The South & Central America epilepsy drugs market was valued at US$ 458.85 million in 2022 and is expected to reach US$ 585.38 million by 2030; it is estimated to grow at a CAGR of 3.1% from 2022 to 2030.
Based on treatment, the South & Central America epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.
In terms of distribution channel, the South & Central America epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.
Based on country, the South & Central America epilepsy drugs market is segmented Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America epilepsy drugs market in 2022.
Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd, are some of the leading companies operating in the South & Central America epilepsy drugs market.
Several Epilepsy Drugs Nearing Patent Expiration Fuels South & Central America Epilepsy Drugs Market
Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.Company Patent Patent Expiration Date Ingredient Treatment
Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy
GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy
Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures
SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies
SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy
SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy
South & Central America Epilepsy Drugs Market Overview
The South & Central America epilepsy drugs market is segmented into the Brazil, Argentina, and the Rest of South & central America. The market growth in this region is attributed due to the rise in number of people affected with epilepsy, growing aging population, ongoing R&D in the field of epilepsy drugs in the region, growing regulatory approvals for new product, and rise in number of accidents and brain injuries in epilepsy drugs.South & Central America Epilepsy Drugs Market Segmentation
The South & Central America epilepsy drugs market is segmented into treatment, distribution channel, and country.Based on treatment, the South & Central America epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.
In terms of distribution channel, the South & Central America epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.
Based on country, the South & Central America epilepsy drugs market is segmented Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America epilepsy drugs market in 2022.
Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd, are some of the leading companies operating in the South & Central America epilepsy drugs market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Epilepsy Drugs Landscape
5. South & Central America Epilepsy Drugs Market - Key Industry Dynamics
6. Epilepsy Drugs Market - South & Central America Market Analysis
7. South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment
8. South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel
9. South & Central America Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis
10. Epilepsy Drugs Market-Industry Landscape
11. Company Profiles
12. Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Alkem Laboratories Ltd
- GSK Plc
- Novartis AG
- Pfizer Inc
- Sanofi SA
- Teva Pharmaceutical Industries Ltd
